NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- - Jingwei Capsules Treat Allergy Symptoms - - Complements Established Boke Nasal Spray Brand - - Diversifies Product Offering with Capsule Formulation -
American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced that the Company has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ("Jingwei"). Jingwei will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.
Jingwei is an effective, long-lasting, tricyclic antihistamine that selectively antagonizes peripheral H1-receptors. This unique mechanism enables Jingwei to quickly alleviate the symptoms associated with rhinitis, chronic urticaria, itching skin and other allergic skin reactions, but without the common antihistamine side-effects. A branded version of Loratadine, Jingwei is currently reimbursable under China's national insurance program.
Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental
Bioengineering, commented, "We are very pleased to be launching the Jingwei
Capsule, which is complementary to our market-leading Boke nasal spray. Its
major competitor is Schering-Plough's Claritine, whose revenue is estimated to
be RMB 1.0 billion at present. Jingwei is an excellent product that is both
effective and safe. With AOBO's well-established distribution network, and
the strength of the Boke brand, we believe that t
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2009 PR Newswire.
All rights reserved